Instructor in Gastrointestinal Oncology, @DanaFarber | combination treatments, functional genomics, RAS inhibition, therapeutic development
Joined February 2020
- Tweets75
- Following387
- Followers828
- Likes521
Pinned Tweet
How should we be drugging RAS and developing clinical combinations for RAS-driven tumors?
@andrewaguirremd, Alice Shaw, @Julien__Dilly, and I have a lot of thoughts (>15,000 words of thoughts), and our mega review is out now at @CD_AACR! Check it out: shorturl.at/ojplo
Online now for the #AACR25 session on Advances in #KRAS Biology in PDAC by session speaker @andrewaguirremd: Response and Resistance to RAS inhibition in Cancer brnw.ch/21wSgTw
Honored to have had the opportunity to share our work at the @AACR Conference on Pancreatic Cancer! KRAS inhibitors are a huge advance, but combination therapies can enhance efficacy and prevent resistance. Lots of exciting progress to come! #AACRpan26
Richard Y. Ebright, MD, PhD retweeted
RAS Inhibition: Response, Resistance, and Rational Combinations—
Kenneth Olive, Arsen Osipov, Rosalie Sears, Richard Ebright, and Qingxiang Lin addressed this topic in a plenary at the AACR Conference on Pancreatic Cancer.
#AACRpan26 @DrArsenOsipov @SearsRosie @RYEbright
Daraxonrasib (aka Rasonque) now approved for pancreatic cancer!! An incredible advance that will bring so much benefit to patients. And it's just the beginning: many more major #KRAS advances to come soon, across many cancer types.
nytimes.com/2026/08/26/scien…
Last year, we reported that KRAS+PRMT5 is synergistic in MTAP-null PDAC (doi.org/10.1158/0008-5472.CA…). Today, the first clinical data for a KRAS/PRMT5 combination was reported, with an incredible 92% ORR.
RAS inhibitors are the present, but combinations are the future!!
$TNGX $RVMD
Happy to have contributed to this new work from @KathleenMulvan4 and @TheSellersLab, showing that KRAS and PRMT5 inhibitors synergy, out now in Cancer Research. KRAS/PRMT5 combos ($RVMD/$TNGX) are now in clinical trials, and results couldn't come sooner!
doi.org/10.1158/0008-5472.CA…
Absolutely incredible to see the massive benefit of RAS inhibition in pancreatic cancer patients, changing the field as I finish my training!! Led by one of my clinical mentors, Brian Wolpin, and received with standing ovation.
Also very cool to be cited in the discussion :)
Richard Y. Ebright, MD, PhD retweeted
Incredible #ASCO26 moment.
Dr. Brian Wolpin, presenter of the daraxonrasib study, received a standing ovation DURING his talk after he stated the survival benefit for PDAC patients. It was sustained. Cheering. I have never see anything like it in the middle of a talk. $RVMD
A new standard for PDAC. Daraxonrasib with 13.2m OS in 2L, and next-generation molecules in development. #RAS
Incredible to see this field changing as I finish training.
Congrats to $RVMD, @NextechInvest + @schroederthilo, and to all the patients!!!
tinyurl.com/4jx88ae8
Happy to have contributed to this new work from @KathleenMulvan4 and @TheSellersLab, showing that KRAS and PRMT5 inhibitors synergy, out now in Cancer Research. KRAS/PRMT5 combos ($RVMD/$TNGX) are now in clinical trials, and results couldn't come sooner!
doi.org/10.1158/0008-5472.CA…
So many important, practice-changing presentations at #ASCO25, but the best part was seeing the work of my incredible @DanaFarber co-fellows 🌟🌟🌟
@SaraKCharMD @SWaliany @tess_omeara @AshleyOdai
Richard Y. Ebright, MD, PhD retweeted
No doubt the best GI Onc division on the planet! So grateful to work with brilliant, kind, and visionary colleagues #ASCO25 @DanaFarber @DanaFarberNews @DFarberYoungCRC @ASCO
Disgusting.
The Trump administration has moved to terminate scores of research grants at Harvard University and its medical school, imperiling scores of research projects and potentially upending the futures of dozens of young scientists. trib.al/jdPxQh1
Richard Y. Ebright, MD, PhD retweeted
56 FDA/CDER novel drug approvals in 2023 (+51% from 2022)
Accelerated approval: 9
Orphan drug designations: 18
Fast track designation: 16
Priority review: 24
Breakthrough therapy: 9
Congrats to the next wave of @DanaFarber / @MGHCancerCenter fellows!! An incredible group coming from @mghmedres! @MattMeiz @DylanJMartini @ben_ouyang @SiennaDurbin
Richard Y. Ebright, MD, PhD retweeted
So excited to start heme/onc fellowship @DanaFarber / @MGHCancerCenter with this phenomenal crew!
Grateful to my family, friends & mentors @StanfordDeptMed @Ron_Witteles @JoelNealMD @HanZhuMD @HwakeleeMD for helping me reach this next stage of my career
Beyond grateful to have had the opportunity to pursue residency at @MGHMedicine with the incredible mentors and coresidents at @mghmedres—so much growth and learning over the last few years.
Per my superlative, maybe one day I’ll put these lessons to use in my Ibiza-based lab 😂
Richard Y. Ebright, MD, PhD retweeted
Congratulations to @MGBUnited on organizing their union with @cirseiu. I call on @MassGenBrigham to hold a fair and transparent election that is free from intimidation.
Richard Y. Ebright, MD, PhD retweeted
Congratulations to @MGBUnited residents, interns and fellows for organizing to form a union with @cirseiu! I stand with these workers in their fight for better wages, benefits and work conditions.
wgbh.org/news/local-news/202…
Richard Y. Ebright, MD, PhD retweeted
Residents and fellows at Mass. General Brigham make patients healthier, and unions make our communities stronger. I applaud the MGB Housestaff, who are unionizing through @cirseiu and advocating for better working conditions, resources, and dignity in their work.